The company's vision is to save 100,000 lives and $1.5 billion in healthcare costs through breath-based diagnostics. In November 2025, Owlstone won an award of up to $49.1 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop at-home tests for early detection of multiple cancers. Research Products and Services are deployed at over 100 sites worldwide with major pharmaceutical companies including AstraZeneca, Actelion, and GlaxoSmithKline.
Cyborg Score Rationale
Series E-stage company founded in 2004 with $167M raised across 17 funding rounds from investors including Horizons Ventures and Aviva. Partnership with FDA (September 2024) to advance volatile organic compound identification and expand the Breath Biopsy VOC Atlas. Strong clinical pipeline and partnerships position the company well, though still pre-commercial for core cancer diagnostics.
Top Insights
ARPA-H POSEIDON award (November 2025) targets development of first-in-class multi-cancer early detection test for 30+ solid tumors using breath and urine samples in home setting.
Cystic Fibrosis Foundation investment of $2.3M (March 2025) to develop breath test for Pseudomonas aeruginosa detection in CF patients.
Technology protected by over 160 granted and pending patents and used in more than 100 research papers.
OMED Health division, founded in 2022, operates patient-centric digital platform for breath-based devices with initial focus on digestive disease and gut health.
Named Competitors
Breath Diagnostics — Non-invasive breath-based lung cancer screening using VOC biomarker analysis
Recent Developments
(May 2026) Series E funding status confirmed with $167M total raised across 17 funding rounds
(March 2025) Secured $2.3M equity investment from Cystic Fibrosis Foundation for PA detection breath test
(November 2025) Won $49.1M ARPA-H award for multi-cancer early detection test development
(September 2024) Partnership with FDA to advance VOC identification and Breath Biopsy VOC Atlas
Open the full interactive Owlstone Medical report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.